Blogs
Healthcare and Medtech Research Reports
Jan 09, 2026
Vitiligo represents a significant yet underrecognized health burden globally. Vitiligo, a chronic autoimmune depigmenting disorder affecting 11.7 million individuals across the leading markets in 2024, is undergoing a seismic shift in therapeutic approaches. The condition typically emerges during the second and thi...
Read More...
May 29, 2017
Vitiligo is a common acquired, idiopathic depigmentation disorder which affects at least 1% to 2% of the population irrespective of sex, race, or age. The onset of this disease occurs between the ages of 10 and 30. In this condition, patients progressively lose their skin color, mostly in patches. The patches ...
Read More...
Intratumoral Cancer Therapy: A Potential Weapon To Fight the Battle Against Cancer
Aug 05, 2026
The Next Wave of Radioligand Therapies: 5 Candidates to Watch
Mar 20, 2026
Newsletter/Whitepaper